Key points are not available for this paper at this time.
Preclinical data supporting the combination of DNA base excision repair inhibitor (TRC102) with DNA alkylating agent (TMZ)
Ahluwalia et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: